Covance Is Now Labcorp Drug Development

We are one global company innovating for millions – together, continuing to bring you more advanced medical breakthroughs.

Learn More

Focal radiation enhances paclitaxel therapy in a mouse model of triple negative breast cancer

Date: 2017

Authors: Maryland Rosenfeld Franklin, Thomas Dailey, and Wilbur R. Leopold 

AACR Annual Meeting

“Focal Radiation Enhances Paclitaxel Therapy in a Mouse Model of Triple Negative Breast Cancer”


Introduction & Background:

  • Triple negative breast cancer (TNBC) accounts for 15-20% of all breast cancers in theUnited States.
  • Patients with TNBC have poorer prognosis and therapeutic intervention is more challenging due to insensitivity to
  • hormonal and anti-HER2 therapies.
  • Therapeutic options for TNBC can include chemotherapy and/or radiation (RT) treatment.
  • Clinical trials evaluating shorter, hypofractionated doses of radiation are being conducted in patients with breast cancer.
  • This study evaluated preclinical activity of paclitaxel in combination with either lower dose, more frequent radiation or higher dose, less frequent radiation.

Let's start a conversation

Contact Us